Australia's Orthocell rises on sales approval application in Hong Kong

Orthocell

10/04/2025 03:24

** Shares of Orthocell OCC.AX rise 14.3% to A$1.435, set for strongest session since January 22, if gains hold

** The biotech firm applies for a regulatory approval to begin sales of its nerve repair product Remplir in Hong Kong

** Co expects to receive approval by Q4 CY2025

** About 2.1 million shares change hands, 1.4x times the 30-day average of 1.5 million

** Stock up 5.2% YTD, including moves in current session

 (Reporting by Jasmeen Ara Shaikh in Bengaluru)

 ((JasmeenAraIslam.Shaikh@thomsonreuters.com;))